MedTrace Logo

The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19

NCT04746092 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 630

Last updated 2021-08-16

No results posted yet for this study

Summary

The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19).

The purpose of the study is to evaluate the capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection and vaccination.

Conditions

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Yair Herishanu, Prof. · Tel-Aviv Sourasky Medical Center

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2022-05-24
Completion
2022-05-24

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746092 on ClinicalTrials.gov